All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 140 of 206 pages ‹ First < 138 139 140 141 142 > Last ›
HSL1783
Bokhari SA.
How to become a biomedical (dental) journalist.
Saudi Med J 2004 Jan;25:
HSL1787
Bennett WM.
Ethical conflicts for physicians treating ESRD patients.
Semin Dial 2004 Jan-Feb;17:(1):1-3
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-139X.2004.17102.x?cookieSet=1
HSL1835
Keim S, Perina DG; CORD Board of Directors.
Council of Emergency Medicine Residency Directors position on interactions between emergency medicine residencies and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11:(1):78
http://www.aemj.org/cgi/content/full/11/1/78
HSL1836
Keim SM, Mays MZ, Grant D.
Interactions between emergency medicine programs and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11:(1):19-26
http://www.aemj.org/cgi/content/full/11/1/19
HSL2318
Hemminki E, Karttunen T, Hovi SL, Karro H.
The drug industry and medical practice--the case of menopausal hormone therapy in Estonia.
Soc Sci Med 2004 Jan;58:(1):89-97
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-48TM3V5-2&_coverDate=01%2F31%2F2004&_alid=307376484&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=be686b45176e3a6cf270c9e1dedc43b1
HSL2385
Friedman LS, Richter ED.
Relationship between conflicts of interest and research results.
J Gen Intern Med 2004 Jan;19:(1):51-6
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2004.30617.x?cookieSet=1
HSL2386
Reinhardt UE.
Perspective: An information infrastructure for the pharmaceutical market.
Health Aff (Millwood) 2004 Jan-Feb;23:(1):107-12
http://content.healthaffairs.org/cgi/content/full/23/1/107
HSL2387
Jeffords JM.
Direct-to-consumer drug advertising: you get what you pay for.
Health Aff (Millwood) 2004 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.253v1
HSL2388
Kelly P.
DTC advertising's benefits far outweigh its imperfections.
Health Aff (Millwood) 2004 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.246v1
HSL2389
Pitts , P. J.
Turning point or tipping point: new FDA draft guidances and the future of DTC advertising
Health Aff 2004 Jan;Suppl Web Exclusives:W4-259-61
HSL2390
Riggs DL, Holdsworth SM, McAvoy DR.
Direct-to-consumer advertising: developing evidence-based policy to improve retention and comprehension.
Health Aff (Millwood) 2004 Jan-Jun;Suppl:
http://content.healthaffairs.org/cgi/reprint/hlthaff.w4.249v1
HSL4712
Malavige GN.
Doctors, drug companies and medical ethics: a Sri Lankan perspective.
Indian J Med Ethics 2004 Jan-Mar;1:(1):26
HSL4713
Guha A.
A comparison of codes of pharmaceutical marketing practices.
Indian J Med Ethics 2004 Jan-Mar;1:(1):19-21
HSL4714
Dabade G.
Unhealthy drug donations.
Indian J Med Ethics 2004 Jan-Mar;1:(1):18
HSL4715
Bal A.
Can the medical profession and the pharmaceutical industry work ethically for better health care?
Indian J Med Ethics 2004 Jan-Mar;1:(1):17
HSL4716
Gulhati CM.
Needed: closer scrutiny of clinical trials.
Indian J Med Ethics 2004 Jan-Mar;1:(1):4-5
HSL4717
Roy N.
Who rules the great Indian drug bazaar?
Indian J Med Ethics 2004 Jan-Mar;1:(1):2-3
HSL7339
Winckler SC.
Drug importation: What's legal, what's safe? - APhA lays out the facts for pharmacists and their patients
Journal of the Pharmacy Society of Wisconsin 2004 Jan-Feb;16-18
HSL7349
Berndt ER.
Perspective: Unique issues raised by drug benefit design.
Health Aff (Millwood) 2004 Jan-Feb;23:(1):103-6
http://content.healthaffairs.org/cgi/content/full/23/1/103
HSL7350
Newhouse JP.
How much should Medicare pay for drugs?
Health Aff (Millwood) 2004 Jan-Feb;23:(1):89-102
http://content.healthaffairs.org/cgi/content/full/23/1/89
HSL7351
Pammolli F, Riccaboni M.
Perspective: Market structure and drug innovation.
Health Aff (Millwood) 2004 Jan-Feb;23:(1):48-50
http://content.healthaffairs.org/cgi/content/full/23/1/48
HSL9735
Ghosh A, Hazra A, Mandal SC.
New drugs in India over the past 15 years: analysis of trends.
Natl Med J India 2004 Jan-Feb;17:(1):10-6
HSL9766
Haynes SV, Dudderidge TJ.
Emergency contraception: the journey so far.
BJOG 2004 Jan;111:(1):91
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1471-0528.2003.00020.x
HSL9777
Sellar PW.
Re: confusion between similarly named eye drops.
Eye 2004 Jan;18:(1):111-2
http://www.nature.com/eye/journal/v18/n1/abs/6700570a.html;jsessionid=2F2DD8EC85EB55D8E0DCACA754334075
HSL9783
Mansour D, Trueman G.
Off-licence prescribing in contraception.
J Fam Plann Reprod Health Care 2004 Jan;30:(1):9-10
http://www.popline.org/ics-wpd/exec/icswppro.dll?BU=http%3A%2F%2Fwww.popline.org%2Fics-wpd%2Fexec%2Ficswppro.dll&QF0=DocNo&QI0=186506&TN=Popline&AC=QBE_QUERY&MR=30&DL=1&&RL=1&&RF=LongRecordDisplay&DF=LongRecordDisplay
HSL9790
Evans L.
Prices, patents and productivity
Current Drug Discovery 2004 Jan;33-35
HSL9989
Business Insights
Harnessing Patient Power: Strategies for speeding drug approval, building and retaining market share
: Business Insights 2004 Jan
http://www.piribo.com/publications/regulation_policy/harnessing_patient_power.html
HSL11461
Etemadi A, Raiszadeh F, Alaeddini F, Azizi F.
Views of Iranian medical journal editors on medical research publication.
Saudi Med J 2004 Jan;25:(1):
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=14968189
HSL13325
Wright RF, Lundstrom WJ.
Physicians' perceptions of pharmaceutical sales representatives: A model for analysing the customer relationship
International Journal of Medical Marketing 2004 Jan;4:(1):29-38
http://www.ingentaconnect.com/content/pal/jmm/2004/00000004/00000001/art00005
HSL16748
Tepper OM, Lurie PL, Wolfe SM
Medical Education Courses in Research-Based Health Activism
Virtual Mentor 2004 Jan;6:1
HSL19516
Keim S, Perina DG
Council of Emergency Medicine Residency Directors Position on Interactions between Emergency Medicine Residencies and the Pharmaceutical Industry
Society for Academic Emergency Medicine 2004 Jan;11:(1):78
http://onlinelibrary.wiley.com/doi/10.1197/j.aem.2003.05.011/abstract
HSL19800
Pammolli F, Riccaboni M
Perspective: Market Structure And Drug Innovation
Health Affairs 2004 Jan;23:(1):48-50
http://content.healthaffairs.org/content/23/1/48.full
HSL19803
Hoadley JF
The Continued Need For Independent Research On Prescription Drugs
Health Affairs 2004 Jan;23:(1):244-249
http://content.healthaffairs.org/content/23/1/244.abstract
HSL19804
Cockburn IM
The Changing Structure Of The Pharmaceutical Industry
Health Affairs 2004 Jan;23:(1):10-22
http://content.healthaffairs.org/content/23/1/10.abstract
HSL19805
Campbell EG, Powers JB, Blumenthal D, Biles B
Inside the Triple Helix: Technology Transfer And Commercialization In The Life Sciences
Health Affairs 2004 Jan;23:(1):64-76
http://content.healthaffairs.org/content/23/1/64.abstract
HSL19806
Belsky L, Emanuel EJ
Conflicts of Interest and Presrving the Objectivity of Scientific Research
Health Affairs 2004 Jan;23:(1):268-270
http://content.healthaffairs.org/content/23/1/268.full
HSL19927
Maignan I, Ferrell OC
Corporate Social Responsibility and Marketing: An Intergrative Framework
JAMS 2004 Jan;32:(1):3-19
http://jam.sagepub.com/content/32/1/3.abstract
HSL19959
Croghan TW, Pittman PM
The Medicine Cabinet: What's In It, Why, And Can We Change The Contents?
Health Affairs 2004 Jan;23:(1):23-33
http://content.healthaffairs.org/content/23/1/23.abstract
HSL19960
Kleinke JD
Access Versus Excess: Value-Based Cost Sharing For Prescription Drugs
Health Affairs 2004 Jan;23:(1):34-47
http://content.healthaffairs.org/content/23/1/34.abstract
HSL19978
Priorities In The Pharmaceutical Industry
Health Affairs 2004 Jan;23:(1):9
http://content.healthaffairs.org/content/23/1/9.full
HSL19979
Pauly MV
Medicare Drug Coverage and Moral Hazard
Health Affairs 2004 Jan;23:(1):113-122
http://content.healthaffairs.org/content/23/1/113.abstract
HSL19980
Soumerai SB
Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid
Health Affairs 2004 Jan;23:(1):135-146
HSL19987
Smith C
Retail Prescription Drug Spending in the National Health Accounts
Health Affairs 2004 Jan;23:(1):160-167
http://content.healthaffairs.org/content/23/1/160.figures-only
HSL20364
Carpenter DP
The Political Economy Of FDA Drug Review: Processing, Politics, And Lessons For Policy
Health Affairs 2004 Jan;23:(1):52-63
http://content.healthaffairs.org/content/23/1/52.abstract
HSL357
Mansfield P, Henry D, Tonkin A.
Single-enantiomer drugs: elegant science, disappointing effects.
Clin Pharmacokinet 2004;43:(5):287-90
http://www.ingentaconnect.com/content/adis/cpk/2004/00000043/00000005/art00002
HSL1148
Welch Cline RJ, Young HN.
Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising.
Health Commun 2004;16:(2):131-57
HSL1164
Szetela AM.
The relationship between health care and mass media in Polish law.
Med Law 2004;23:(1):9-17
HSL1640
Collins K.
Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health.
Perspect Biol Med 2004 Win;47:(1):100-9
http://www.ncbi.nlm.nih.gov/pubmed/15061171
HSL1789
Baker D.
A free market solution for prescription drug crises.
Int J Health Serv 2004;34:(3):517-26
HSL1796
Drug costs: research and development costs: the great illusion.
Prescrire Int. 2004;13:(69):32-6
HSL1887
Huh J, DeLorme DE, Reid LN.
Media credibility and informativeness of direct-to-consumer prescription drug advertising.
Health Mark Q 2004;21:(3):27-61
HSL1889
Kalb S.
[Influence of pharmaceutical advertising on the physician: A contribution to ethics in medicine].
Wurzbg Medizinhist Mitt 2004;23:446-56:
HSL2048
Gardner H.
Changing Minds: The Art and Science of Changing Our Own Mind and Other People's Minds
Harvard: Harvard Business School Press 2004
http://harvardbusinessonline.hbsp.harvard.edu/b02/en/common/item_detail.jhtml;jsessionid=YKOILMM2CR4H2AKRGWDSELQ?id=7095
HSL2380
Edwards B.
Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
Drug Saf. 2004;27:(8):609-17
HSL2381
Goldman SA.
Communication of medical product risk: how effective is effective enough?
Drug Saf 2004;27:(8):519-34
HSL2382
Hall TS.
Reimagining the learned intermediary rule for the new pharmaceutical marketplace.
Seton Hall Law Rev 2004;35:(1):193-261
HSL2383
Miller M, Supranowicz P, Targowski M, Piechowiak-Modrzejewska E.
[Evaluation of quality and accessibility of health education materials. I. The opinion of health personnel]
Rocz Panstw Zakl Hig. 2004;55:(2):115-23
HSL2384
Parojcic D.
[Patent medicines and its advertising in Serbia during the second half of the 19th and first half of the 20th century]
Rev Hist Pharm (Paris). 2004;52:(342):229-46
HSL2397
Green CJ, Kazanjian A, Helmer D.
Informing, advising, or persuading? An assessment of bone mineral density testing information from consumer health websites
Int J Technol Assess Health Care. 2004 Spring;20(2): 2004 Spr;20:(2):156-66
HSL3680
Anonymous .
Merck & co invents new syndromedinformation deprivation.
Scrip. 2004;2983:5
HSL3688
Canadian Institute for Health Information.
Drug expenditure in Canada 1985 to 2003.
Ottawa: Canadian Institute for Health Information. 2004
http://www.cihi.ca.
HSL3753
Meyer U.
[Pharmaceutical industry and "New German Medicine" ("Neue Deutsche Heilkunde")]
Med Ges Gesch 2004;23:165-82
HSL3776
Srivastava R, Chandra A, Kumar G.
Strategic imperatives for globalization of industries in developing countries: an Indian pharmaceutical industry example.
Health Mark Q 2004;22:(1):57-69
HSL3777
Tengilimoglu D, Kisa A, Ekiyor A.
The pharmaceutical sales rep/physician relationship in Turkey: ethical issues in an international context.
Health Mark Q 2004;22:(1):21-39
HSL3778
Tengilimoglu D, Korkmaz S, Akinci F, Parsons AL.
Managerial implications of medical sales representative perceptions of job duties, job qualifications, and other performance-related issues.
Health Mark Q 2004;22:(2):3-26
HSL3803
Puska P, Lehtomaki P, Eckstein H, Juvonen H.
[Sources of medicine for developing countries].
Duodecim 2004;120:(23):2833-40
HSL4760
Tett SE.
A perspective on Australia's National Medicines Policy.
Can J Clin Pharmacol 2004 Spr;11:(1):e28-38
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=5025&uid=15226524&db=PubMed&url=http://www.cjcp.ca/pdf/Australia_National_MedicinesDEMO.pdf
HSL4846
[No authors listed].
Ethical code of the pharmaceutical industry in Slovakia. (Excerpts).
Med Etika Bioet 2004 Aut;11:(3-4):11-22
HSL5308
American Academy of Pain Medicine Council on Ethics
AAPM Ethics Charter
: American Academy of Pain Medicine Council on Ethics 2004
http://www.painmed.org/productpub/pdfs/EthicsCharter.pdf
HSL5328
Dunning D, Heath C, Suls JM.
Flawed self-assessment: implications for education and the workplace.
Psychol Sci Public Interest 2004;5:69-106
HSL5371
Poon EG, Blumenthal D, Jaggi T, Honour MM, Bates DW, Kaushal R.
Overcoming barriers to adopting and implementing computerized physician order entry systems in U.S Hospitals
Health Aff. 2004;23:184-190
http://content.healthaffairs.org/cgi/content/full/23/4/184
HSL19334
Stell LK.
Two cheers for physicians' conflicts of interest.
Mt Sinai J Med 2004;71:(4):236-42
http://www.ncbi.nlm.nih.gov/pubmed/15365589
HSL5781
Foote M.
Guidelines and policies for medical writers in the biotech industry: an update on the controversy.
Biotechnol Annu Rev 2004;10:259-64:
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7CTS-4DN8YX3-7&_coverDate=12%2F31%2F2004&_alid=431466823&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=18058&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=867f3a71a0241a0bf5b894eb3c7bdec4
HSL19380
Hemminki E, Karttunen T, Hovi SL, Karro H.
The drug industry and medical practice--the case of menopausal hormone therapy in Estonia.
Soc Sci Med 2004;58:(1):89-97
http://linkinghub.elsevier.com/retrieve/pii/S0277953603001503
HSL7323
Chi J.
Should PBMs disclose their contracts? - Here are pros, cons
Drug-Top (Drug-Topics) 2004;148:(10):52
HSL7325
Bronstein D, Frei R.
Debate heats up on drug reimportation
Pharmacy-Practice-News 2004;31:(4):
HSL7326
Minnesota governor's Web site promotes cut-rate Canadian rxs
Pharmacy Times 2004;70:(40):10
HSL7327
Berry D.
N.C. halts illegal prescription businesses
Pharmacy-Today 2004;10:(3):43
HSL7328
FDA wants ad changes
Pharmacy Times 2004;70:(4):
HSL7330
Zwillich T.
Drugmakers vow to hold election-year ground in Rx pricing
Drug Topics 2004;148:(4):74
HSL7332
Vitry A.
Is Australia free from direct-to-consumer advertising?
Australian Prescriber 2004;27:(1):4-6
HSL7336
Medicines Australia code of conduct: breaches
Australian Prescriber 2004;27:(1):6-8
HSL7337
Holmes ER, Desselle SP.
Evaluating the balance of persuasive and informative content within product-specific print direct-to-consumer ads
Drug Information Journal 2004;38:(1):83-98
HSL7338
Kayne S.
Alzheimers patients get a cheap deal
New Zealand Pharmacy 2004;24:(2):17
HSL8827
Goozner M.
The $800 Million Pill: The Truth behind the Cost of New Drugs
Berkeley, CA: University of California Press 2004
http://www.ucpress.edu/books/pages/10083.html
HSL8828
Le Carre J.
The Constant Gardener : A Novel
: Scribner/Simon & Schuster 2004
http://www.simonsays.com/content/book.cfm?tab=1&pid=427053
HSL8829
Angell M.
The Truth About the Drug Companies: How They Deceive Us and What to Do About It
New York: Random House 2004
http://www.randomhouse.com/acmart/?view=about
HSL8830
Avorn J.
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs
New York: Random House 2004
http://www.randomhouse.com/catalog/display.pperl?isbn=9780375414831
HSL9047
Daemmrich A
Pharmacopolitics: Drug Regulation in the US and Germany
Chapel Hill, NC: Univ North Carolina Press 2004
http://uncpress.unc.edu/books/T-7301.html
HSL9673
Wang LN.
Challenges of medicines for children
Pharmaceutical Journal 2004;272:(7301):680
HSL9674
Kayne S.
Opportunity knocks in animal health
Pharmaceutical Journal 2004;272:(7300):647
HSL9675
Lumb J.
Students are better than they think at conducting home medication reviews
Pharmaceutical Journal 2004;272:(7300):644
HSL9676
Wang LN.
New ways to ensure patient loyalty
Pharmaceutical Journal 2004;272:(7300):635-636
HSL9677
Lancet concludes that OTC statins are not the answer
Pharmaceutical Journal 2004;272:(7300):632
HSL9679
Aronson JK.
Medication errors resulting from the confusion of drug names
Expert Opinion on Drug Safety 2004;3:(3):167-172
HSL9684
Wilce H.
Temazepam capsules: What was the problem?
Australian Prescriber 2004;27:(3):58-59
HSL9685
Watson MC, Bond CM.
The evidence-based supply of non-prescription medicines: Barriers and beliefs
International Journal of Pharmacy Practice 2004;12:(2):65-72
HSL9688
York A.
Thinking inside the box
Lancet Oncology 2004;5:(6):332
HSL9689
Cholesterol agents lead all therapeutic classes in prescription drug sales
Drug Benefit Trends 2004;16:(5):232-233
HSL9690
Nash DB.
Outpatient drug safety: The final frontier
P and T 2004;29:(5):
Page 140 of 206 pages ‹ First < 138 139 140 141 142 > Last ›
